Michael Gray
Director of Finance/CFO chez Carmot Therapeutics, Inc.
Fortune : 121 424 $ au 31/03/2024
Profil
Michael P.
Gray currently works at The American Institute of Certified Public Accountants, as Member and Carmot Therapeutics, Inc., as Chief Operating & Financial Officer from 2023.
Mr. Gray also formerly worked at Arsanis, Inc., as President, CEO, Chief Financial Officer & Director from 2018 to 2019, X4 Pharmaceuticals, Inc., as President, Chief Executive Officer & CFO from 2018 to 2019, Therapeutics Acquisition Corp., as Independent Director, Curis, Inc., as Secretary, Chief Financial & Business Officer from 2014 to 2016, Tetraphase Pharmaceuticals, Inc., as Chief Financial Officer & Senior Vice President, Reprogenesis, Inc., as Controller from 1998 to 2000, Imara, Inc., as Chief Financial & Operating Officer, and Enliven Therapeutics, Inc., as Chief Financial & Operating Officer from 2019 to 2023.
Mr. Gray received his undergraduate degree from Bryant University and Masters Business Admin degree from F.W.
Olin Graduate School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/02/2023 | 6 903 ( 0,02% ) | 121 424 $ | 31/03/2024 |
Postes actifs de Michael Gray
| Sociétés | Poste | Début |
|---|---|---|
The American Institute of Certified Public Accountants
 The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY. | Corporate Officer/Principal | - |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Director of Finance/CFO | 06/06/2023 |
Anciens postes connus de Michael Gray
| Sociétés | Poste | Fin |
|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Director of Finance/CFO | 23/02/2023 |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | Chief Executive Officer | 13/03/2019 |
| X4 PHARMACEUTICALS, INC. | Chief Executive Officer | 13/03/2019 |
| CURIS, INC. | Director of Finance/CFO | 29/02/2016 |
Reprogenesis, Inc.
 Reprogenesis, Inc. BiotechnologyHealth Technology Reprogenesis, Inc., located in Cambridge, Massachusetts developes tissue engineered therapies to treat unmet medical needs. The Company has proprietary technology utilizing the combination of cells and biomaterials to restore, repair or replace lost tissue or physiological function. The Company has a broad preclinical and clinical pipeline of products in the areas of urology, cardiovascular biology and plastic and reconstructive surgery. ChondrogelTM is its most advanced product | Comptroller/Controller/Auditor | 01/07/2000 |
Formation de Michael Gray
| Bryant University | Undergraduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CURIS, INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| ENLIVEN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
Arsanis, Inc.
Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | Health Technology |
The American Institute of Certified Public Accountants
The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY. | Commercial Services |
Reprogenesis, Inc.
Reprogenesis, Inc. BiotechnologyHealth Technology Reprogenesis, Inc., located in Cambridge, Massachusetts developes tissue engineered therapies to treat unmet medical needs. The Company has proprietary technology utilizing the combination of cells and biomaterials to restore, repair or replace lost tissue or physiological function. The Company has a broad preclinical and clinical pipeline of products in the areas of urology, cardiovascular biology and plastic and reconstructive surgery. ChondrogelTM is its most advanced product | Health Technology |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA. | Health Technology |
Therapeutics Acquisition Corp.
 Therapeutics Acquisition Corp. Financial ConglomeratesFinance Therapeutics Acquisition Corp. is a blank check company with a purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Peter Kolchinsky and Matthew Hammond on April 15, 2020 and is headquartered in Boston, MA. | Finance |
